Sensei Biotherapeutics, Inc.
SNSE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.98 | 0.50 | -1.00 | -0.89 |
| FCF Yield | -10.08% | -8.32% | -4.30% | -1.00% |
| EV / EBITDA | -8.13 | -11.38 | -18.53 | -90.57 |
| Quality | ||||
| ROIC | -77.23% | -52.08% | -45.04% | -25.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.94 | 0.80 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 22.94% | 18.16% | -21.87% | -70.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.20 | 0.20 | 0.14 |
| Interest Coverage | -362.38 | -257.39 | -229.17 | -55.94 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -826.72 | -1,082.85 | -903.01 | -1,308.67 |